NLS Pharmaceutics CEO Issues Letter to Shareholders

Provided By PR Newswire

Last update: Jun 16, 2025

ZURICH , June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.